Telix Commences Phase III Clinical Trial of Prostate Cancer Therapy

Go back to Telix Commences Phase III Clinical Trial of Prostate Cancer Therapy
TRANS-LUX CORPORATION (NYSE: TLX) Delayed: 0.29 --0 (-0%)
Previous Close $0.29    52 Week High $2.18 
Open $25.79    52 Week Low $0.30 
Day High $0.29    P/E N/A 
Day Low $0.29    EPS $-3.32 
Volume 373,793